Last updated: April 5, 2026
The FDA Peptide Reclassification, Explained
What actually happened, what it means and what to do.
14 peptides may be returning to legal compounding. But “may be” is doing a lot of work in that sentence.
Jump to Tracker →The bottom line (if you're in a hurry)
- In late 2023, the FDA restricted 19 popular peptides from being compounded by pharmacies, citing safety concerns.
- On February 27, 2026, HHS Secretary RFK Jr. announced approximately 14 of those 19 peptides would be returned to legal compounding status.
- As of today, no formal FDA rule change has been published. The announcement reflects intent, not action.
- Five peptides were already referred for review in September 2024 (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank).
- Even if reclassified, these peptides will NOT be FDA-approved. They’ll be compoundable with a prescription. That’s different.
- Do not source peptides from gray market vendors based on this news.
What Happened in 2023 — The Original Restriction
In late 2023, the FDA updated its bulk drug substances list, moving 19 popular peptides from Category 1 (eligible for compounding) to Category 2 (flagged as presenting safety concerns, effectively prohibited from compounding). This meant compounding pharmacies could no longer legally prepare these compounds. Consumers who had been getting peptides through legitimate compounding channels lost access.
The 19 compounds included some of the most widely used peptides in clinical practice: BPC-157, TB-500, CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank, Semax, GHK-Cu, KPV, DSIP, Epithalon, AOD-9604 and others.
The Category System
| Category | What It Means | Can Pharmacies Compound It? | Consumer Impact |
|---|---|---|---|
| Category 1 | Adequate safety and usage data | Yes, with valid prescription | Accessible through licensed provider + pharmacy |
| Category 2 | Flagged as presenting potential safety risks | No, effectively prohibited | Cannot access through standard compounding |
| Category 3 | Under evaluation, insufficient information | Under review | Uncertain, check current status |
| FDA-Approved | Completed full clinical trials | Available as standard prescription | Available at standard pharmacies, insurance may cover |
Category 1 is NOT FDA approval. A peptide moving from Category 2 to Category 1 means pharmacies can compound it again. You're still relying on your provider's clinical judgment and the quality of the compounding pharmacy — not on FDA endorsement.
The February 2026 Announcement
On February 27, 2026, HHS Secretary RFK Jr. announced on the Joe Rogan Experience that approximately 14 of the 19 restricted peptides would be returned to legal compounding status. This generated enormous optimism. But announcements are not regulations. As of today, no formal rule change has been published.
Five peptides were already referred to the Pharmacy Compounding Advisory Committee (PCAC) in September 2024: CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604 and Selank. These are furthest along in the reclassification process. The remaining compounds expected to move back to Category 1 include BPC-157, TB-500, Semax, GHK-Cu, KPV, DSIP, Epithalon, Dihexa and PE-22-28 — but none have been formally reclassified yet.
A Note on GLP-1s — Different Rules, Different Story
GLP-1 medications like semaglutide and tirzepatide are on a completely separate regulatory track from the Category 2 peptide reclassification. They are FDA-approved drugs, not compounds awaiting reclassification. Do not conflate these two situations — they are moving in opposite directions.
The GLP-1 compounding story: compounding pharmacies were temporarily allowed to compound semaglutide and tirzepatide during FDA-declared drug shortages. Those shortages have ended — tirzepatide in late 2024, semaglutide in February 2025 — and the FDA has aggressively enforced against compounded copies.
The enforcement timeline has been swift: enforcement discretion ended for 503A pharmacies in April 2025 and 503B facilities in May 2025. Over 50 warning letters went out in September 2025. In February 2026, the FDA publicly stated its intent to take action against non-FDA-approved GLP-1 drugs. On April 1, 2026, the FDA issued further clarification reinforcing that compounded copies are not permitted now that supply has stabilized, and confirmed DOJ involvement in enforcement.
The only remaining legal pathway for compounded semaglutide is a narrow patient-specific exception under 503A: when a prescriber documents that the FDA-approved product cannot be used for a specific individual patient. Brand-name Wegovy costs approximately $1,349/month with no generics expected until early 2030s.
What You Should Do Right Now
Do not rush to source peptides based on announcements.
The formal rule change has not been published. Acting prematurely could mean paying for something not yet legally compoundable.
Do not buy "research peptides" from unregulated vendors.
Gray market products carry real risks: no purity guarantee, no sterility assurance, no medical oversight.
Start the conversation with a licensed provider now.
Get baseline labs, develop a plan that can be executed when reclassification is formalized. See our compound profiles for evidence-based information.
Subscribe to our regulatory tracker below.
Updates as developments happen.
FAQ
Is BPC-157 legal now?
Not yet. It remains Category 2. Expected to return to Category 1 but the formal rule change hasn’t been published. When it is, BPC-157 will be compoundable with a physician’s prescription — not available over the counter.
Can my doctor prescribe peptides right now?
Physicians can prescribe FDA-approved peptide medications (semaglutide, tirzepatide, bremelanotide) through standard pharmacies. For Category 2 peptides, the legal situation for compounding is currently ambiguous. Discuss current availability with your provider.
What’s the difference between 503A and 503B pharmacies?
503A pharmacies are traditional compounding pharmacies filling individual prescriptions. 503B outsourcing facilities operate under stricter FDA oversight and can produce larger batches. Both can legally compound Category 1 substances.
Stay ahead of the FDA.
Regulatory updates as developments happen. New compound profiles weekly. No spam. No sales pitches.
Peptide Regulatory Tracker
Current FDA compounding status for all tracked compounds.
Last Updated: April 5, 2026
| Compound▲ | Current Status | PCAC Referred? | Compoundable Now? | Notes |
|---|---|---|---|---|
| Semaglutide | FDA-Approved | N/A | Compounding restricted | Shortage ended Feb 2025. April 1, 2026: FDA confirmed enforcement + DOJ involvement. Brand cost $935–$1,349/mo. |
| Tirzepatide | FDA-Approved | N/A | Compounding restricted | Same enforcement trajectory as semaglutide. Brand cost ~$1,059/mo. |
| AOD-9604 | Category 2, PCAC-referred | Yes (Sep 2024) | No | PCAC-referred |
| CJC-1295 | Category 2, PCAC-referred | Yes (Sep 2024) | No | Furthest along in reclassification |
| Ipamorelin | Category 2, PCAC-referred | Yes (Sep 2024) | No | Furthest along in reclassification |
| Selank | Category 2, PCAC-referred | Yes (Sep 2024) | No | Approved in Russia. PCAC-referred. Nasal. |
| Thymosin Alpha-1 | Category 2, PCAC-referred | Yes (Sep 2024) | No | Approved in 30+ countries. PCAC-referred. |
| BPC-157 | Category 2 → Expected Category 1 | No | No | Expected to return to legal compounding pending formal FDA action |
| Dihexa | Category 2 → Expected Category 1 | No | No | Cognitive. Note: one key study retracted — transparency moment. |
| DSIP | Category 2 → Expected Category 1 | No | No | Sleep peptide |
| Epithalon | Category 2 → Expected Category 1 | No | No | Telomere/longevity research |
| GHK-Cu | Category 2 → Expected Category 1 | No | No | Long topical safety history |
| KPV | Category 2 → Expected Category 1 | No | No | Anti-inflammatory tripeptide |
| PE-22-28 | Category 2 → Expected Category 1 | No | No | Cognitive. Very early research. |
| Semax | Category 2 → Expected Category 1 | No | No | Approved in Russia. Nasal delivery. |
| TB-500 | Category 2 → Expected Category 1 | No | No | Expected to return pending formal action |